<DOC>
	<DOC>NCT00844727</DOC>
	<brief_summary>Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.</brief_summary>
	<brief_title>Coxib-inhibition of Duodenal Polyp Growth in FAP</brief_title>
	<detailed_description />
	<mesh_term>Rofecoxib</mesh_term>
	<criteria>FAP patient with previous colectomy and confirmed polyposis Pregnancy Malignancy NSAID hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>